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Abstract A recently identified membrane-type 6 matrix metal-
loproteinase (MT6-MMP) has a hydrophobic stretch of 24
amino acids at the C-terminus. This hydrophobicity pattern is
similar to glycosyl-phosphatidyl inositol (GPI)-anchored MMP,
MT4-MMP, and other GPI-anchored proteins. Thus, we tested
the possibility that MT6-MMP was also a GPI-anchored
proteinase. Our results showed that MT6-MMP as well as
MT4-MMP were labeled with [3H]ethanolamine indicating the
presence of a GPI unit with incorporated label. In addition,
phosphatidyl inositol-specific phospholipase C treatment released
MT6-MMP from the surface of transfected cells. These results
strongly indicate that MT6-MMP is a GPI-anchored protein.
Since two members of MT-MMPs are now assigned as GPI-
anchored proteinase, MT-MMPs can be subgrouped into GPI
type and transmembrane type. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Matrix metalloproteinases (MMPs), also called matrixins,
are a family of Zn2-dependent metalloendopeptidase that is
involved in the degradation of extracellular matrix (ECM) in
physiological and pathological conditions [1,2]. To date, 21
mammalian MMPs have been identi¢ed by cDNA cloning
[3^8], and they can be sub-grouped into 15 soluble-type
MMPs and 6 membrane-types (MT-MMPs). In MT-MMP
subfamily, MT1-, MT2-, MT3-, MT5-MMPs are type I trans-
membrane proteins as they have transmembrane domain and
about 20 amino acids cytoplasmic tail. On the other hand,
MT4-MMP is a glycosyl-phosphatidyl inositol (GPI)-an-
chored proteinase [9]. GPI-anchored proteins attach to the
plasma membrane via 2^3 fatty acids contained in the GPI
molecule. Such a protein is synthesized as a precursor having
a 15^20 hydrophobic amino acid stretch at the C-terminus
(GPI-signal). The hydrophobic amino acid stretch is cleaved
o¡ in the ER lumen, and the ectodomain is transferred to the
GPI moiety [10]. Thus, the mature GPI-anchored protein has
neither transmembrane nor intracellular domains.
Recently, the sixth member of MT-MMP, MT6-MMP/leu-
kolysin/MMP-25, has been identi¢ed [7,8]. The highest amino
acid sequence identity to other MT-MMPs is with MT4-MMP
(45^49%) followed by MT1-MMP (39%). MT6-MMP is ex-
pressed in leukocytes among normal tissue cells [7] and in
colon carcinoma and astrocytoma among tumor cell lineage
[8]. MT6-MMP was also reported to activate proMMP-2
(progelatinase A) [8]. However, the function of the enzyme
remains to be determined.
The hydrophobicity plot of the deduced amino acid se-
quence at the C-terminus indicates that the putative trans-
membrane domain of MT6-MMP locates at the end of the
C-terminus, similar to MT4-MMP. This suggests the possibil-
ity that MT6-MMP may be a GPI-anchored protein. In this
paper, we report that MT6-MMP is the second GPI-anchored
proteinase in the MMP family.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM) was from Nissui
Pharmaceutical (Tokyo, Japan). Ham’s F-12 medium was from Gibco
Life Technologies (MD, USA). FuGENE61 was from Roche Molec-
ular Biochemicals (Basle, Switzerland). Phosphatidylinositol-speci¢c
phospholipase C (PI-PLC) was from Oxford Glyco Sciences (Abing-
don, UK). Monoclonal mouse anti-FLAG epitope IgGs, M1 and M2,
was from Sigma (MO, USA). Alexa488-conjugated goat anti-mouse
IgG was from Jackson Immuno Research Laboratories (PA, USA).
2.2. Construction of FLAG-tagged human MT6-MMP
Partial sequence of MT6-MMP was screened from dbEST library,
and the full-length human cDNA (accession no: AB042328) was ob-
tained from placenta cDNA library of Marathon-Ready cDNA
(Clontech, CA, USA) by 5P- and 3P-RACE method. To detect MT6-
MMP protein by anti-FLAG antibody, FLAG epitope (Asp-Tyr-Lys-
Asp-Asp-Asp-Asp-Lys)-tagged MT6-MMP expression constructs were
generated. The FLAG epitope was inserted immediately downstream
of the furin cleavage motif of MT6-MMP (following Arg107) (MT6-
F). MT1-F and MT4-F constructs were made as described previously
[9]. All the mutant constructs were generated by polymerase chain
reaction using overlap extension method of Ho et al. [11], and all
polymerase chain reaction products were con¢rmed by DNA sequenc-
ing. All the mutated fragments were ligated into the original MT-
MMP cDNA and whole cDNA was subcloned into the pSG5 expres-
sion vector (Stratagene, CA, USA).
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2.3. Cell culture and transfection
COS1 cells and CHO-K1 cells were cultured in DMEM or Ham’s
F-12 medium supplemented with 10% FBS and Kanamysin in a hu-
midi¢ed 37‡C incubator. Sixteen hours before the transfection was
performed, cells were re-seeded in 6-well plates at 2U105/well. Ex-
pression vectors for each protein were transfected using FuGENE61
according to the manufacturer’s instructions. After 48 h, the cells were
harvested and subjected to each experiment.
2.4. Western blotting
Samples were separated by SDS/PAGE, and the proteins in the gel
were transferred to a nitrocellulose membrane (Hybond-ECL, Amer-
sham Life Science, Buckinghamshire, UK). After blocking with 10%
fat-free dry milk in TBS (20 mM Tris^HCl, pH 7.5, 150 mM NaCl),
the membrane was probed with anti-FLAG M2 monoclonal antibody
(3 Wg/ml) to detect FLAG-tagged MT-MMPs. The membrane was
further probed with alkaline phosphatase-conjugated anti-mouse
IgG to visualize FLAG-tagged MT-MMPs.
2.5. [3H]Ethanolamine incorporation, immunoprecipitation and
autoradiography
The experiments were performed as described previously [9]. Brie£y,
COS1 cells transfected with expression plasmids for MT6-F, MT4-F,
MT1-F, or vector alone were incubated with [3H]ethan-1-ol-2-amine
(Amersham Life Science, Buckinghamshire, UK) (80 WCi/ml) for 24 h.
Cells were lysed in the RIPA bu¡er (10 mM Tris^HCl, pH 8.0,
150 mM NaCl, 1% NP-40, 0.1% sodium deoxycolicolate, 0.1% SDS,
10 mM EDTA, 2 mM PMSF, 10 WM E-64, 0.02% NaN3) at room
temperature (RT), and lysates were subjected to immunoprecipitation
using anti-FLAG M2 conjugated beads (Sigma) at RT for 2 h. The
immunoprecipitated samples were subjected to SDS^PAGE and
3H-labeled materials were detected on X-ray ¢lm after reaction of
the gel with EN3HANCE (NEN1 Life Science Products, MA,
USA). The FLAG-tagged MT-MMPs in the samples were visualized
by Western blotting using anti-FLAG M2 antibody.
3. Results
3.1. Characterization of MT6-MMP as a GPI-anchored
protein
The amino acid alignment of human MT6-MMP with other
MT-MMPs and GPI-anchored proteins shows similar pattern
of hydrophobicity at the C-terminus to MT4-MMP and GPI-
anchored proteins (Fig. 1). Therefore, we addressed the pos-
sibility that MT6-MMP was expressed on the cell surface as a
GPI-anchored protein. The synthesis of the GPI-membrane
anchor unit includes the incorporation of ethanolamine for
bridging the COOH-terminal amino acid and the glycan struc-
ture [10]. Thus, GPI-anchored proteins can be labeled meta-
bolically with [3H]ethanolamine [10]. A FLAG epitope of
Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys was inserted downstream
of the furin cleavage site of MT6-MMP (following Arg107,
MT6-F) as well as MT1- and MT4-MMP (MT1-F and
MT4-F, respectively). COS1 cells were transfected with the
expression plasmids for MT6-F, MT4-F, and MT1-F, and
[3H]ethanolamine was added to culture medium to metabol-
ically label the cells. The cells were then lysed in RIPA bu¡er
and subjected for immunoprecipitation using anti-FLAG M2
IgG-conjugated beads. As shown in Fig. 2, Western blotting
analyses of these samples using anti-FLAG M2 antibody re-
vealed major doublet bands at 62 and 58 kDa for MT6-F, a
doublet of 71 and 67 kDa for MT4-F, and a 63- and 60-kDa
band for MT1-F (WB). When these samples were analyzed by
autoradiography, as expected, [3H]ethanolamine was speci¢-
Fig. 1. Comparison of the C-terminal end of MT6-MMP to other GPI-anchored proteins. Amino acid sequences of the C-terminal end that in-
clude the transmembrane region of MT1^6-MMPs, human Thy1 (hThy1) (accession number 135830), GPI-anchor type human N-CAM (neural
cell adhesion molecule, hNCAM120) (accession number 127861), and human urokinase receptor (huPAR) (accession number 465003) are listed
and aligned. Amino acids in the expected transmembrane region according to hydrophobicity plots are indicated in bold and underlined.
Fig. 2. Incorporation of [3H]ethanolamine into MT6-MMP. COS1
cells, transiently transfected with the expression vectors for hMT6-
F, hMT4-F, or hMT1-F, or with the vector alone were incubated
with [3H]ethan-1-ol-2-amine, and the cell lysates were subjected to
immuno-precipitation using anti-FLAG M2 conjugated beads as de-
scribed in Section 2. The samples were subjected to autoradiography
(AR) or Western blotting (WB) using M2 antibody.
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cally incorporated into both MT6-F and MT4-F, but not into
MT1-F (AR, lanes 1 and 2). The labeled band corresponds to
one of the two bands at 60- or 67-kDa species for both MT6-
F and MT4-F, respectively, detected by anti-FLAG M2 anti-
body (WB, lanes 1 and 2). We have previously shown that
71-kDa species of MT4-MMP that is not labeled with
[3H]ethanolamine is a precursor for GPI-anchoring likely to
have C-terminal hydrophobic stretch intact [9]. Like MT4-
MMP, the upper bands detected on the Western blot in
MT6-MMPs (62 kDa) that are not labeled with
[3H]ethanolamine are likely to correspond to the precursor
for GPI-anchoring, and the 58-kDa species is the GPI-an-
chored MT6-MMP.
We then tested the susceptivity of MT6-MMP expressed on
the cell surface to the bacterial PI-PLC that is a hallmark of
GPI-anchored protein [10]. As shown in Fig. 3, PI-PLC treat-
ment of the transfected cells cleared o¡ the cell surface located
MT6-F as well as MT4-F. In contrast, the type I transmem-
brane proteinase MT1-MMP was insensitive to PI-PLC treat-
ment. Taken together, we conclude that human MT6-MMPs
is a GPI-anchored proteinase like MT4-MMP.
3.2. MT6-MMP does not activate proMMP-2
It has been shown that co-expression of proMMP-2 and
MT6-MMP results in proMMP-2 activation [8]. However,
co-expression of MT6-F with proMMP-2 in COS1 cells did
not result in the activation of proMMP-2 at all as shown in
Fig. 4 (lane 3). In contrast, MT1-F activated proMMP-2 into
65-kDa active species e¡ectively (lane 2). The same result was
obtained when puri¢ed proMMP-2 was added to the culture
medium of transfected COS1 or CHO-K1 cells (data not
shown). Therefore, we conclude that MT6-MMP, at least in
our condition using COS1 or CHO-K1 cells, does not activate
proMMP-2.
Fig. 3. Release of MT6-MMP from the cell surface by PI-PLC treatment. CHO-K1 cells were transfected with the expression plasmids for
hMT6-F, hMT4-F, hMT1-F or the vector without insert. After 48 h, the cells in 8-well chamber slide were treated with or without PI-PLC
(10 U/ml) in DMEM without FBS at 37‡C for 1 h. The cells were then ¢xed, and MT-MMPs were immunolocalized using anti-FLAG M1
antibody without permeabilization of the cells. Cy3-conjugated anti-mouse IgG was used to visualize the signals and analyzed by confocal mi-
croscopy (Bio-Rad). The broad area of the staining pattern in each treatment is shown (U47). For PI-PLC treated cells, re£ection images of
same area were also shown.
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4. Discussion
In the present study, we have shown that MT6-MMP is a
GPI anchored MMP. Among 6 MT-MMPs, MT4-MMP and
MT6-MMP are GPI-anchored proteins, and thus MT-MMPs
can be now further classi¢ed into two subgroups: transmem-
brane-type and GPI-type. The signi¢cance of the di¡erences in
the anchoring methods to the plasma membrane is still un-
known, but it is likely that the cytoplasmic domain of the
transmembrane-type MT-MMP may have a role in the regu-
lation of the MT-MMPs’ activity on the cell surface [12]. GPI-
type MT-MMPs, on the contrary, utilize GPI-moiety to local-
ize in microdomain structure of the plasma membrane which
is rich in cholesterol and glycosphingolipids [9,13^15]. The
enrichment of GPI-anchored proteins in microdomain was
shown not to be ecto-domain dependent, but GPI-moiety-de-
pendent manner [14]. Thus, di¡erent GPI-anchored proteins
can be localized in the same site on the plasma membrane. In
fact, MT4-MMP was shown to be colocalized with non-re-
lated GPI-anchored protein, uPAR [9], and may be localized
with MT6-MMP as well. The uPAR has previously been
shown to associate with L2-integrin (CD18), and this interac-
tion was shown to be important for leukocyte adhesion to the
endothelial cells [16], local ¢brin degradation [17] and cell
migration [18]. The GPI-anchored proteinases, MT4-MMP
and MT6-MMP, co-localized with uPAR in the same micro-
domain clusters. Thus, they may co-operate in conjunction
with cell adhesion molecules, such as CD18.
GPI-anchored MMP in other species can be also found
according to its amino acid sequence. One MT-MMP found
in Caenorhabditis elegans, MMP-Y19 (GenBank accession
number AB007817) [19], is likely to be a GPI-type because
of its hydrophobicity pattern of the amino acid sequence of its
C-terminal end (493-PRNEKLVLNSSSSHFSLIYATITILI-
LIF-521). By searching C. elegans genome database, none of
MT-MMPs other than MMP-Y19 was found. If MMP-Y19 is
the only MT-MMP in C. elegans, GPI-type MT-MMP may be
an ancestor of transmembrane-type MT-MMPs during evolu-
tion, and may suggest that GPI-anchored MMPs play an
important role in certain fundamental biological phenomen-
on.
In contrast to the report by Velasco et al. [8], MT6-MMP
did not activate proMMP-2 in this study. The di¡erence be-
tween the results may be due to di¡erent experimental con-
ditions used such as di¡erent cell types. Nevertheless, the
MT6-MMP does not seem to activate proMMP-2 e¡ectively.
To activate proMMP-2 on the cell surface, a complex of MT-
MMPs with TIMP-2 is required to attract proMMP-2 on the
cell surface [20,21]. It also requires TIMP-2 free MT-MMPs
near the MT-MMPs/TIMP-2/proMMP-2 complex [20]. Thus,
inability of the activation of proMMP-2 by MT6-MMP may
be explained by a defect in either steps. Activation of
proMMP-2 by MT1-MMP [22], MT2-MMP [23], MT3-
MMP [24], and MT5-MMP [6] has been reported. Thus acti-
vation of proMMP2 may be a common catalytic property of
MT-MMPs. On the other hand, MT1-MMP gene knock out
mice were de¢cient in proMMP-2 activation in vivo tissue
[25]. Thus, it is likely that the major in vivo activator of
proMMP-2 is MT1-MMP rather than the other MT-MMPs.
In conclusion, our results indicate that MT6-MMP is the sec-
ond GPI-anchored MMP in mammal. Anchoring MT4-MMP
and MT6-MMP to the plasma membrane through GPI-an-
chor may indicate a unique biological character, regulation
and function of these enzymes among MT-MMPs.
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